Semaglutide pancreatic cancer risk to be assessed in large Nordic cohort study
Background
Type 2 diabetes (T2D) patients are at increased risk for various complications, including certain cancers. Concerns have been raised regarding a potential association between GLP-1 receptor agonists like semaglutide and pancreatic cancer risk, necessitating rigorous post-market surveillance. Current evidence is mixed, prompting the need for large-scale, real-world data to clarify this potential safety signal and inform clinical practice. This study addresses the gap in long-term safety data for semaglutide regarding pancreatic cancer.
Study Design
A multi-national, non-interventional cohort study will analyze healthcare data from Denmark, Sweden, and Norway, covering the period 2018-2023. Researchers will compare new users of semaglutide with new users of active comparators: sulphonylureas, sodium-glucose co-transporter 2 inhibitors, and insulin (subdivided into basal only or basal + bolus/premix). Propensity score matching will be used to balance baseline characteristics between groups. Data from national prescription, cancer, and patient registries will identify drug exposure, pancreatic cancer cases, and covariates. This study is designated as a post-authorisation safety study (PASS).
Why It Matters
This large-scale, real-world cohort study is critical for clarifying the long-term safety profile of semaglutide concerning pancreatic cancer risk in type 2 diabetes patients. If the study finds no increased risk, it would strengthen confidence in semaglutide's safety. Conversely, if a signal emerges, it would necessitate further investigation and potentially impact prescribing guidelines. For clinicians and patients, these future findings will provide crucial evidence to weigh the benefits of semaglutide for glycemic control and weight management against any potential long-term risks, informing shared decision-making.
semaglutide
type-2-diabetes
pancreatic-cancer
cohort-study
safety
glp-1-agonist